iRhythm Technologies, Inc.

iRhythm Technologies develops and provides ambulatory cardiac monitoring solutions for arrhythmia detection and diagnosis. The company's primary offering is the Zio ECG monitoring service, a wearable long-term cardiac monitoring platform designed for continuous, uninterrupted patient monitoring. The Zio service includes several key components: the Zio monitor (wearable device), advanced AI-assisted analysis utilizing FDA-cleared deep-learning algorithms verified by Qualified Cardiac Technicians (QCTs), and comprehensive physician-ready reports. The service supports both continuous monitoring and event-triggered detection capabilities. iRhythm serves healthcare professionals including cardiologists, electrophysiologists, and primary care providers. The company has processed data from over 12 million patients and 2 billion hours of curated heartbeat data. Key technological features include FDA-cleared AI algorithms (available in the US, EU, Switzerland, UK, and Japan), integration with electronic health records (EHR) systems, and a clinician portal (ZioSuite) for report interpretation and patient management. The MyZio patient app provides digital symptom logging, educational content, and wear compliance support. Clinical evidence indicates the Zio LTCM service achieves the highest diagnostic yield of specified arrhythmias compared to other monitoring strategies, lowest likelihood of retesting, and 99% physician agreement with comprehensive end-of-wear reports. The company maintains robust clinical validation through prospective and retrospective studies including the AVALON and CAMELOT studies. iRhythm supports patients, healthcare professionals, and international inquiries through dedicated support channels.